Teva prolia® (denosumab) biosimilar candidate is accepted for review by u.s. fda and eu ema

Tel aviv, israel, oct. 08, 2024 (globe newswire) -- teva pharmaceutical industries ltd. (nyse and tase: teva) today announced that the united states (u.s.) food and drug administration (fda) has accepted, and the european medicines agency (ema) has validated, applications for tvb-009p, a biosimilar candidate to prolia® (denosumab).1
TEVA Ratings Summary
TEVA Quant Ranking